Vertex Pharmaceuticals Investor Presentation — April 2021

Document content

©2021 Vertex Pharmaceuticals IncorporatedAPRIL 29, 2021global.vrtx.com ©2021 Vertex Pharmaceuticals Incorporated 2AGENDA

Michael Partridge, Senior Vice President, Investor Relations

CEO Perspective and R&D Update

Reshma Kewalramani , M.D., CEO and President

Stuart Arbuckle, Executive Vice President and Chief Commercial and Operations Officer

Charlie Wagner, Executive Vice President and Chief Financial Officerglobal.vrtx.com ©2021 Vertex Pharmaceuticals Incorporated 3SAFE HARBOR STATEMENT & NON- GAAP FINANCIAL MEASURES

This presentation contains forward -looking statements as defined in the Private Securities Litigation Reform Act of 1995, includ ing, without limitation, the information provided regarding future financial

performance and operation, the section captioned "Full -Year Updated 2021 Financial Guidance" and statements regarding ( i) anticipated regulatory filings, data submissions, and approvals, (ii) future label

expansions, (iii) the expectations, development plans and anticipated timelines for the company’s therapies and pipeline prog rams, including clinical site activations, patient enrollment and data availability, (iv)

the company's expectations regarding the effects COVID -19 will have on its business and operations, (v) expectations for the con tinued launch, uptake and reimbursement of KAFTRIO, (vi) expectations for the

collaborations with CRISPR, including expectations regarding completion of enrollment in the CTX001 clinical studies, anticip ated benefits of the collaborations and anticipated timing of product access for future

patients, (vii) expectations for uptake of and expanded access to the company’s medicines, including additional reimbursement agreements, (viii) expectations for an increase in the number of CF patients treated

with our medicines, (ix) expectations for VX -548, including our plans to advance VX -548 into Phase 2 proof -of-concept studies in the second half of 2021, (x) expectations for the transactions contemplated by the

amended collaboration with CRISPR, including satisfaction of closing conditions, antitrust clearance, anticipated upfront and milestone payments to CRISPR, and anticipated future activities of the parties, (xi)

expected effect on our expenses upon the closing of the transaction contemplated by the amended collaboration with CRISPR, an d (xii) anticipated internal and external development. While Vertex believes the

forward -looking statements contained in this presentation are accurate, these forward -looking statements represent the company's beliefs only as of the date of this presentation and there are a number of risks

and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward -looking statements. Those risks and uncertainties include, among other things, that